[go: up one dir, main page]

HK1118007A1 - Kim-1 antibodies for treatment of th2-mediated conditions - Google Patents

Kim-1 antibodies for treatment of th2-mediated conditions

Info

Publication number
HK1118007A1
HK1118007A1 HK08106807.2A HK08106807A HK1118007A1 HK 1118007 A1 HK1118007 A1 HK 1118007A1 HK 08106807 A HK08106807 A HK 08106807A HK 1118007 A1 HK1118007 A1 HK 1118007A1
Authority
HK
Hong Kong
Prior art keywords
kim
antibodies
treatment
mediated conditions
mediated
Prior art date
Application number
HK08106807.2A
Other languages
English (en)
Inventor
Paul D Rennert
Patricia Mccoon
Veronique Bailly
Alexey Lugovskoy
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HK1118007A1 publication Critical patent/HK1118007A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK08106807.2A 2005-03-02 2008-06-19 Kim-1 antibodies for treatment of th2-mediated conditions HK1118007A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65778905P 2005-03-02 2005-03-02
PCT/US2006/007441 WO2006094134A2 (en) 2005-03-02 2006-03-02 Kim-1 antibodies for treatment of th2-mediated conditions

Publications (1)

Publication Number Publication Date
HK1118007A1 true HK1118007A1 (en) 2009-01-30

Family

ID=36648475

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08106807.2A HK1118007A1 (en) 2005-03-02 2008-06-19 Kim-1 antibodies for treatment of th2-mediated conditions

Country Status (15)

Country Link
US (2) US8206705B2 (de)
EP (2) EP1865985B1 (de)
JP (2) JP2008531719A (de)
KR (1) KR101213894B1 (de)
CN (2) CN103751780A (de)
AT (1) ATE478707T1 (de)
AU (2) AU2006218489B2 (de)
BR (1) BRPI0608254A2 (de)
CA (1) CA2599967C (de)
DE (1) DE602006016413D1 (de)
HK (1) HK1118007A1 (de)
IL (1) IL185653A (de)
NZ (1) NZ562045A (de)
WO (1) WO2006094134A2 (de)
ZA (1) ZA200708372B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008064031A2 (en) * 2006-11-13 2008-05-29 Government Of The United States, As Represented Bythe Secretary Of The Department Of Health And Human Services Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
CA2833785C (en) 2011-04-21 2022-06-07 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
MA43135A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes pour le du traitement du cancer
AU2016343805A1 (en) * 2015-10-30 2018-06-07 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (de) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5622861A (en) 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6165733A (en) 1996-05-23 2000-12-26 Chiron Corporation γ II adaptin
SI0907735T2 (sl) 1996-05-24 2010-01-29 Biogen Idec Inc Modulatorji tkivne regeneracije
EP0948597A4 (de) 1996-11-01 2002-07-10 Human Genome Sciences Inc Menschliches, Schleimhaut-spezifisches Addressin-Zelladhäsionsmolekül (MAdCAM-1) und dessen Spleissvarianten
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
AU7624798A (en) 1996-12-06 1998-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
ES2386262T3 (es) 1998-01-23 2012-08-14 F. Hoffmann-La Roche Ag Anticuerpos contra IL-12 humana
CN1550232A (zh) 1998-03-11 2004-12-01 杂环酰胺化合物在制备自身免疫性疾病抑制剂中的用途
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2001098481A2 (en) 2000-06-16 2001-12-27 Biogen, Inc. Renal regulatory elements and methods of use thereof
NZ530457A (en) 2001-06-01 2007-12-21 Biogen Idec Inc Molecules and methods for inhibiting shedding of KIM-1
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
EP1406653A4 (de) 2001-06-29 2005-05-04 Univ Leland Stanford Junior T-zellen-regulationsgene und verfahren zur verwendung davon
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
CA2479732A1 (en) 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
CA2512138C (en) 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
DK1613750T3 (en) * 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
US20050119210A1 (en) 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005097211A2 (en) 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions as adjuvants to improve immune responses to vaccines and methods of use
US8025557B2 (en) 2009-02-27 2011-09-27 Illinois Tool Works Inc. Sanding clay

Also Published As

Publication number Publication date
EP2251037A1 (de) 2010-11-17
US20100150905A1 (en) 2010-06-17
US20130089539A1 (en) 2013-04-11
CA2599967A1 (en) 2006-09-08
JP2012131825A (ja) 2012-07-12
NZ562045A (en) 2010-12-24
AU2011202405A1 (en) 2011-06-09
CN103751780A (zh) 2014-04-30
CA2599967C (en) 2014-10-21
AU2011202405B2 (en) 2013-03-28
JP2008531719A (ja) 2008-08-14
ZA200708372B (en) 2008-12-31
CN101166542A (zh) 2008-04-23
AU2006218489B2 (en) 2011-02-24
BRPI0608254A2 (pt) 2009-12-08
US8206705B2 (en) 2012-06-26
IL185653A0 (en) 2008-01-06
EP2251037B1 (de) 2015-01-14
KR20070110411A (ko) 2007-11-16
WO2006094134A3 (en) 2006-10-19
KR101213894B1 (ko) 2012-12-20
EP1865985B1 (de) 2010-08-25
EP1865985A2 (de) 2007-12-19
WO2006094134A2 (en) 2006-09-08
AU2006218489A1 (en) 2006-09-08
IL185653A (en) 2013-04-30
DE602006016413D1 (de) 2010-10-07
ATE478707T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
EP1928453A4 (de) Verfahren und zusammensetzungen zur prävention und behandlung von nierenerkrankungen
EP2046315A4 (de) Therapeutische mittel zur behandlung maligner lymphome
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ZA200705297B (en) Methods and compositions for treating amyloid related diseases
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
IL178435A0 (en) Beta-carbolines useful for treating inflammatory disease
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
ZA200706113B (en) Method for the treatment of copper-bearing materials
WO2006081516A3 (en) USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
HK1112157A1 (en) Apparatus for caring dead body
HK1118007A1 (en) Kim-1 antibodies for treatment of th2-mediated conditions
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP1865952A4 (de) Histaminhaltige zusammensetzung zur behandlung von allergischen erkrankungen
ZA200610628B (en) Composition for diagnosing and treating circulatory system diseases
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160302